- Home
- NNN vs LEGN Comparison
NNN vs LEGN Comparison
Compare NNN & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNN
- LEGN
- Stock Information
- Founded
- NNN 1984
- LEGN 2014
- Country
- NNN United States
- LEGN United States
- Employees
- NNN N/A
- LEGN N/A
- Industry
- NNN Real Estate Investment Trusts
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- NNN Real Estate
- LEGN Health Care
- Exchange
- NNN Nasdaq
- LEGN Nasdaq
- Market Cap
- NNN 8.6B
- LEGN 9.1B
- IPO Year
- NNN N/A
- LEGN 2020
- Fundamental
- Price
- NNN $42.18
- LEGN $38.19
- Analyst Decision
- NNN Hold
- LEGN Strong Buy
- Analyst Count
- NNN 6
- LEGN 13
- Target Price
- NNN $46.17
- LEGN $81.46
- AVG Volume (30 Days)
- NNN 1.4M
- LEGN 1.6M
- Earning Date
- NNN 10-31-2024
- LEGN 11-12-2024
- Dividend Yield
- NNN 5.50%
- LEGN N/A
- EPS Growth
- NNN 1.10
- LEGN N/A
- EPS
- NNN 2.16
- LEGN N/A
- Revenue
- NNN $867,015,000.00
- LEGN $520,183,000.00
- Revenue This Year
- NNN N/A
- LEGN $110.04
- Revenue Next Year
- NNN $4.31
- LEGN $77.16
- P/E Ratio
- NNN $19.54
- LEGN N/A
- Revenue Growth
- NNN 6.99
- LEGN 122.96
- 52 Week Low
- NNN $38.49
- LEGN $38.02
- 52 Week High
- NNN $49.57
- LEGN $70.13
- Technical
- Relative Strength Index (RSI)
- NNN 30.60
- LEGN 29.40
- Support Level
- NNN $41.72
- LEGN $38.94
- Resistance Level
- NNN $43.33
- LEGN $41.87
- Average True Range (ATR)
- NNN 0.89
- LEGN 2.20
- MACD
- NNN -0.14
- LEGN -0.30
- Stochastic Oscillator
- NNN 19.85
- LEGN 1.74
About NNN NNN REIT Inc.
NNN REIT Inc is a real estate investment trust that invests in and develops properties throughout the United States. The company generates revenue from leasing properties to tenants, including convenience stores, automotive services, fitness centers, theatres, restaurants, and banks. Rents from convenience stores and restaurants contribute the majority proportion of total revenue, followed by automotive services, entertainment venues, and others. maximum of the company's properties are located in the South and Southeast of the United States.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.